Cost-effectiveness of adding magnetic resonance imaging to rheumatoid arthritis management

Archives of Internal Medicine

Volumn 171, Issue 7, 2011, Pages 657-667

  Suter, Lisa G ^a,b   Fraenkel, Liana ^a,b   Scott Braithwaite, R ^c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYCHLOROQUINE SULFATE; METHOTREXATE; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG DOSE ESCALATION; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SIMULATION; TREATMENT RESPONSE;

ARTHRITIS, RHEUMATOID; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DECISION TREES; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; MODELS, ECONOMIC; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

EID: 79955069103     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2011.115     Document Type: Article

References (91)

1. Helmick CG, Felson DT, Lawrence RC, et al; National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: part I. Arthritis Rheum. 2008;58(1):15-25.
2. Birnbaum H, Pike C, Kaufman R, Maynchenko M, Kidolezi Y, Cifaldi M. Societal cost of rheumatoid arthritis patients in the US. Curr Med Res Opin. 2010;26 (1):77-90.
3. Benucci M, Cammelli E, Manfredi M, Saviola G, Baiardi P, Mannoni A; Associazione Medici-Scandicci. Early rheumatoid arthritis in Italy: study of incidence based on a two-level strategy in a sub-area of Florence (Scandicci-Le Signe). Rheumatol Int. 2008;28(8):777-781.
4. Myasoedova E, Crowson CS, Kremers HM, Therneau TM, Gabriel SE. Is the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955-2007. Arthritis Rheum. 2010;62(6):1576-1582.
5. Ramos-Remus C, Sierra-Jimenez G, Skeith K, et al. Latitude gradient influences the age of onset in rheumatoid arthritis patients. Clin Rheumatol. 2007;26(10): 1725-1728.
6. Möttönen T, Hannonen P, Leirisalo-Repo M, et al; FIN-RACo Trial Group. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. Lancet. 1999;353(9164):1568-1573.
7. Wolfe F, Ross K, Hawley DJ, Roberts FK, Cathey MA. The prognosis of rheumatoid arthritis and undifferentiated polyarthritis syndrome in the clinic: a study of 1141 patients. J Rheumatol. 1993;20(12):2005-2009.
8. Michaud K, Messer J, Choi HK, Wolfe F. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7, 527 patients. Arthritis Rheum. 2003;48(10):2750-2762.
9. Ostendorf B, Scherer A, Mödder U, Schneider M. Diagnostic value of magnetic resonance imaging of the forefeet in early rheumatoid arthritis when findings on imaging of the metacarpophalangeal joints of the hands remain normal. Arthritis Rheum. 2004;50(7):2094-2102.
10. Brown AK, Quinn MA, Karim Z, et al. Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum. 2006;54(12):3761-3773.
11. McQueen FM, Benton N, Perry D, et al. Bone edema scored on magnetic resonance imaging scans of the dominant carpus at presentation predicts radiographic joint damage of the hands and feet six years later in patients with rheumatoid arthritis. Arthritis Rheum. 2003;48(7):1814-1827.
12. Bøyesen P, Haavardsholm EA, Ostergaard M, van der Heijde D, Sesseng S, Kvien TK. MRI in early rheumatoid arthritis: synovitis and bone marrow oedema are independent predictors of subsequent radiographic progression. Ann Rheum Dis. 2011;70(3):428-433.
13. Boesen M, Østergaard M, Cimmino MA, Kubassova O, Jensen KE, Bliddal H. MRI quantification of rheumatoid arthritis: current knowledge and future perspectives. Eur J Radiol. 2009;71(2):189-196.
14. Saag KG, Teng GG, Patkar NM, et al; American College of Rheumatology. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59(6):762-784.
15. Landewe ́ RB, Boers M, Verhoeven AC, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum. 2002;46(2):347-356.
16. van der Heijde DM, van Leeuwen MA, van Riel PL, et al. Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum. 1992;35(1):26-34.
17. Fransen J, Stucki G, van Riel PLCM. Rheumatoid arthritis measures: Disease Activity Score (DAS), Disease Activity Score-28 (DAS28), Rapid Assessment of Disease Activity in Rheumatology (RADAR), and Rheumatoid Arthritis Disease Activity Index (RADAI). Arthritis Rheum. 2003;49(5S):S214- S224.
18. Mäkinen H, Hannonen P, Sokka T. Definitions of remission for rheumatoid arthritis and review of selected clinical cohorts and randomised clinical trials for the rate of remission. Clin Exp Rheumatol. 2006;24(6)(suppl 43):S22-S28.
19. McQueen FM, Stewart N, Crabbe J, et al. Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals progression of erosions despite clinical improvement. Ann Rheum Dis. 1999;58(3):156-163.
20. Hoving JL, Buchbinder R, Hall S, et al. A comparison of magnetic resonance imaging, sonography, and radiography of the hand in patients with early rheumatoid arthritis. J Rheumatol. 2004;31(4):663-675.
21. de Vries-Bouwstra J, Le Cessie S, Allaart C, Breedveld F, Huizinga T. Using predicted disease outcome to provide differentiated treatment of early rheumatoid arthritis. J Rheumatol. 2006;33(9):1747-1753.
22. Conaghan PG, O'Connor P, McGonagle D, et al. Elucidation of the relationship between synovitis and bone damage: a randomized magnetic resonance imaging study of individual joints in patients with early rheumatoid arthritis. Arthritis Rheum. 2003;48(1):64-71.
23. Lindegaard HM, Vallø J, Hørslev-Petersen K, Junker P, Østergaard M. Lowcost, low-field dedicated extremity magnetic resonance imaging in early rheumatoid arthritis: a 1-year follow-up study. Ann Rheum Dis. 2006;65(9):1208-1212.
24. Hetland ML, Ejbjerg B, Hørslev-Petersen K, et al; CIMESTRA Study Group. MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis: results from a 2-year randomised controlled trial (CIMESTRA). Ann Rheum Dis. 2009;68(3):384-390.
25. Hammer HB, Haavardsholm EA, Bøyesen P, Kvien TK. Bone erosions at the distal ulna detected by ultrasonography are associated with structural damage assessed by conventional radiography and MRI: a study of patients with recent onset rheumatoid arthritis. Rheumatology (Oxford). 2009;48(12):1530-1532.
26. Syversen SW, Gaarder PI, Goll GL, et al. High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Ann Rheum Dis. 2008;67(2):212-217.
27. Jansen LMA, van der Horst-Bruinsma IE, van Schaardenburg D, Bezemer PD, Dijkmans BAC. Predictors of radiographic joint damage in patients with early rheumatoid arthritis. Ann Rheum Dis. 2001;60(10):924-927.
28. Jansen LMA, van Schaardenburg D, van der Horst-Bruinsma I, van der Stadt RJ, de Koning MHMT, Dijkmans BAC. The predictive value of anti-cyclic citrullinated peptide antibodies in early arthritis. J Rheumatol. 2003;30(8):1691-1695.
29. McQueen FM, Benton N, Crabbe J, et al. What is the fate of erosions in early rheumatoid arthritis? tracking individual lesions using x rays and magnetic resonance imaging over the first two years of disease. Ann Rheum Dis. 2001;60 (9):859-868.
30. Østergaard M, Hansen M, Stoltenberg M, et al. Magnetic resonance imaging- determined synovial membrane volume as a marker of disease activity and a predictor of progressive joint destruction in the wrists of patients with rheumatoid arthritis. Arthritis Rheum. 1999;42(5):918-929.
31. Haavardsholm EA, Bøyesen P, Østergaard M, Schildvold A, Kvien TK. Magnetic resonance imaging findings in 84 patients with early rheumatoid arthritis: bone marrow oedema predicts erosive progression. Ann Rheum Dis. 2008;67(6):794-800.
32. Mundwiler ML, Maranian P, Brown DH, et al. The utility of MRI in predicting radiographic erosions in the metatarsophalangeal joints of the rheumatoid foot: a prospective longitudinal cohort study. Arthritis Res Ther. 2009;11(3):R94. doi: 10.1186/ar2737.
33. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000; 343(22):1586-1593.
34. Goekoop-Ruiterman YPM, De Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005;52(11):3381-3390.
35. Taylor PC, Steuer A, Gruber J, et al. Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis. Arthritis Rheum. 2004;50(4):1107-1116.
36. Saunders SA, Capell HA, Stirling A, et al. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies. Arthritis Rheum. 2008;58(5):1310-1317.
37. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med. 2007;146(6):406-415.
38. van der Heijde D, Klareskog L, Landewe R, et al. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 2007;56(12): 3928-3939.
39. Korpela M, Laasonen L, Hannonen P, et al; FIN-RACo Trial Group. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study. Arthritis Rheum. 2004;50(7):2072-2081.
40. Du Pan SM, Dehler S, Ciurea A, Ziswiler H-R, Gabay C, Finckh A; Swiss Clinical Quality Management Physicians. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum. 2009;61(5):560-568.
41. Ferraccioli GF, Gremese E, Tomietto P, Favret G, Damato R, Di Poi E. Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step-up combination therapy (methotrexate, cyclosporin A, sulphasalazine) or monotherapy for three years. Rheumatology (Oxford). 2002;41(8): 892-898.
42. Lerndal T, Svensson B. A clinical study of CPH 82 vs methotrexate in early rheumatoid arthritis. Rheumatology (Oxford). 2000;39(3):316-320.
43. Sarzi-Puttini P, D'Ingianna E, Fumagalli M, et al. An open, randomized comparison study of cyclosporine A, cyclosporine A + methotrexate and cyclosporine A + hydroxychloroquine in the treatment of early severe rheumatoid arthritis. Rheumatol Int. 2005;25(1):15-22.
44. Lehman AJ, Esdaile JM, Klinkhoff AV, et al; METGO Study Group. A 48-week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: results of the METGO study. Arthritis Rheum. 2005;52(5):1360-1370.
45. van Dongen H, van Aken J, Lard LR, et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebocontrolled trial. Arthritis Rheum. 2007;56(5):1424-1432.
46. Dougados M, Combe B, Cantagrel A, et al. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis. 1999;58(4):220-225.
47. Marchesoni A, Battafarano N, Arreghini M, et al. Step-down approach using either cyclosporin A ormethotrexate as maintenance therapy in early rheumatoid arthritis. Arthritis Rheum. 2002;47(1):59-66.
48. Lee S-S, Park Y-W, Park JJ, et al. Combination treatment with leflunomide and methotrexate for patients with active rheumatoid arthritis. Scand J Rheumatol. 2009;38(1):11-14.
49. Lipsky PE, van der Heijde DMFM, St Clair EW, et al; Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 2000; 343(22):1594-1602.
50. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med. 1999;130(6): 478-486.
51. Smolen JS, Han C, Bala M, et al; ATTRACT Study Group. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the Anti-tumor Necrosis Factor Trial in Rheumatoid Arthritis With Concomitant Therapy Study. Arthritis Rheum. 2005;52(4):1020-1030.
52. Barrera P, van der Maas A, van Ede AE, et al. Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-α antibody compared with methotrexate in long-standing rheumatoid arthritis. Rheumatology (Oxford). 2002;41(4):430-439.
53. Klareskog L, van der Heijde D, de Jager JP, et al; TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) Study Investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363(9410):675-681.
54. Khanna D, Park GS, Paulus HE, et al. Reduction of the efficacy of methotrexate by the use of folic acid: post hoc analysis from two randomized controlled studies. Arthritis Rheum. 2005;52(10):3030-3038.
55. Gerards AH, Landewe RBM, Prins APA, et al. Cyclosporin A monotherapy versus cyclosporin A and methotrexate combination therapy in patients with early rheumatoid arthritis: a double blind randomised placebo controlled trial. Ann Rheum Dis. 2003;62(4):291-296.
56. St Clair EW, van der Heijde DMFM, Smolen JS, et al; Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004; 50(11):3432-3443.
57. Quinn MA, Conaghan PG, O'Connor PJ, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52(1): 27-35.
58. Agency for Healthcare Research and Quality. Nationwide inpatient sample. Healthcare Cost and Utilization Project Web site. http://hcupnet.ahrq.gov/.Accessed September 30, 2009.
59. Marra CA, Woolcott JC, Kopec JA, et al. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc Sci Med. 2005; 60(7):1571-1582.
60. Brown JS, Neumann PJ, Papadopoulos G, Ruoff G, Diamond M, Menzin J. Migraine frequency and health utilities: findings from a multisite survey. Value Health. 2008;11(2):315-321.
61. Sackett DL, Torrance GW. The utility of different health states as perceived by the general public. J Chronic Dis. 1978;31(11):697-704.
62. Blumenschein K, Johannesson M. Relationship between quality of life instruments, health state utilities, and willingness to pay in patients with asthma. Ann Allergy Asthma Immunol. 1998;80(2):189-194.
63. Verhoeven AC, Boers M, van der Linden S. Responsiveness of the core set, response criteria, and utilities in early rheumatoid arthritis. Ann Rheum Dis. 2000; 59(12):966-974.
64. Söderlin MK, Kautiainen H, Skogh T, Leirisalo-Repo M. Quality of life and economic burden of illness in very early arthritis: a population based study in southern Sweden. J Rheumatol. 2004;31(9):1717-1722.
65. Kobelt G, Jönsson L, Lindgren P, Young A, Eberhardt K. Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis. Arthritis Rheum. 2002;46(9):2310-2319.
66. Wells G, Boers M, Shea B, et al; International League of Associations for Rheumatology; OMERACT/ILAR Task Force on Generic Quality of Life; Life Outcome Measures in Rheumatology. Sensitivity to change of generic quality of life instruments in patients with rheumatoid arthritis: preliminary findings in the generic health OMERACT study. J Rheumatol. 1999;26(1):217-221.
67. CPT Code/Relative Value Search (based on 2009 CPT codes and Medicare payment information) for CPT codes 73218-73223, 73100, 73120, 73620, 85651, 85652, 86200, and 86431. https://catalog.ama-assn.org/Catalog/cpt/cpt_search.jsp?locality=_n. Accessed August 5, 2009.
68. Birnbaum HG, Barton M, Greenberg PE, et al. Direct and indirect costs of rheumatoid arthritis to an employer. J Occup Environ Med. 2000;42(6):588-596.
69. Wolfe F, Michaud K, Choi HK, Williams R. Household income and earnings losses among 6, 396 persons with rheumatoid arthritis. J Rheumatol. 2005;32(10): 1875-1883.
70. Puolakka K, Kautiainen H, Pekurinen M, et al; FIN-RACo Trial Group. Monetary value of lost productivity over a five year follow up in early rheumatoid arthritis estimated on the basis of official register data on patients' sickness absence and gross income: experience from the FIN-RACo trial. Ann Rheum Dis. 2006;65 (7):899-904.
71. Li X, Gignac MA, Anis AH. The indirect costs of arthritis resulting from unemployment, reduced performance, and occupational changes while at work. Med Care. 2006;44(4):304-310.
72. Merkesdal S, Ruof J, Huelsemann JL, et al. Indirect cost assessment in patients with rheumatoid arthritis (RA): comparison of data from the Health Economic Patient Questionnaire HEQ-RA and insurance claims data. Arthritis Rheum. 2005; 53(2):234-240.
73. Newhall-Perry K, Law NJ, Ramos B, et al; Western Consortium of Practicing Rheumatologists. Direct and indirect costs associated with the onset of seropositive rheumatoid arthritis. J Rheumatol. 2000;27(5):1156-1163.
74. Griffiths RI, Bar-Din M, MacLean CH, Sullivan EM, Herbert RJ, Yelin EH. Medical resource use and costs among rheumatoid arthritis patients receiving diseasemodifying antirheumatic drug therapy. Arthritis Care Res. 2000;13(4):213-226.
75. 2001 Drug Topics Red Book. Montvale, NJ: Medical Economics; 2001.
76. Choi HK, Seeger JD, Kuntz KM. A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis. Arthritis Rheum. 2000;43(10):2316-2327.
77. Real earnings in February 2008 [press release]. Washington, DC: Bureau of Labor Statistics, US Dept of Labor; March 14, 2008. USDL 08-0335.
78. National Vital Statistics System. Centers for Disease Control and Prevention Web site. 2004. http://www.cdc.gov/nchs/nvss.htm. Accessed July 7, 2009.
79. Gabriel SE, Crowson CS, Kremers HM, et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum. 2003; 48(1):54-58.
80. Wolfe F, Mitchell DM, Sibley JT, et al. The mortality of rheumatoid arthritis. Arthritis Rheum. 1994;37(4):481-494.
81. Bureau of Labor Statistics Consumer Price Index inflation calculator. http://www.bls.gov/data/inflation_calculator.htm. Accessed March 2, 2010.
82. Braithwaite RS, Meltzer DO, King JT Jr, Leslie D, Roberts MS. What does the value of modern medicine say about the $50, 000 per quality-adjusted life-year decision rule? Med Care. 2008;46(4):349-356.
83. Murray CJL, Evans DB, Acharya A, Baltussen RMPM. Development ofWHOguidelines on generalized cost-effectiveness analysis. Health Econ. 2000;9(3):235-251.
84. Matsui T, Shimada K, Ozawa N, et al. Diagnostic utility of anti-cyclic citrullinated peptide antibodies for very early rheumatoid arthritis. J Rheumatol. 2006;33 (12):2390-2397.
85. Tanaka Y, Takeuchi T, Mimori T, et al; RRR Study Investigators. Extended report: discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis. 2010;69(7):1286-1291.
86. Felson DT, Anderson JJ, Boers M, et al; The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum. 1993;36(6):729-740.
87. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology: preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995; 38(6):727-735.
88. Gülfe A, Geborek P, Saxne T. Response criteria for rheumatoid arthritis in clinical practice: how useful are they? Ann Rheum Dis. 2005;64(8):1186-1189.
89. Turnbull L, Brown S, Harvey I, et al. Comparative Effectiveness of MRI in Breast Cancer (COMICE) trial: a randomised controlled trial. Lancet. 2010;375(9714): 563-571.
90. Oei EHG, Nikken JJ, Ginai AZ, et al. Costs and effectiveness of a brief MRI examination of patients with acute knee injury. Eur Radiol. 2009;19(2):409-418.
91. Levin DC, Rao VM, Parker L, Frangos AJ, Sunshine JH. Ownership or leasing of MRI facilities by nonradiologist physicians is a rapidly growing trend. J AmColl Radiol. 2008;5(2):105-109.